TAK-906 Maleate

DRUG3 trials

Sponsors

Millennium Pharmaceuticals, Inc.

Conditions

Diabetes Mellitus and Gastroparesis, Idiopathic GastroparesisDiabetic GastroparesisHealthy ParticipantsIdiopathic Gastroparesis

Phase 1

A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

CompletedNCT03161405

Millennium Pharmaceuticals, Inc.Healthy Participants

Start: 2017-06-05End: 2017-07-10Updated: 2019-01-11

Phase 2

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

CompletedNCT03268941

Millennium Pharmaceuticals, Inc.Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

Start: 2017-09-26End: 2018-03-09Updated: 2021-01-06

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

CompletedNCT03544229

Millennium Pharmaceuticals, Inc.Diabetic Gastroparesis, Idiopathic Gastroparesis

Start: 2018-10-14End: 2021-07-15Updated: 2022-11-16

Related Papers

Randomized clinical trial: A phase 2b controlled study of the efficacy and safety of trazpiroben (TAK‐906) for idiopathic or diabetic gastroparesis

Neurogastroenterology & Motility2023-08-038 citations

The pharmacokinetics of oral trazpiroben (<scp>TAK</scp>‐906) after organic anion transporting polypeptide <scp>1B1</scp>/<scp>1B3</scp> inhibition: A phase I, randomized study

Clinical and Translational Science2022-04-236 citations

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole

Clinical and Translational Science2022-02-262 citations

Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D<sub>2</sub>/D<sub>3</sub> Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants

Clinical Pharmacology in Drug Development2021-12-291 citations

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D<sub>2</sub>/D<sub>3</sub> Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor.

2021-07-123 citations

Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK‐906), a dopamine D<sub>2</sub>/D<sub>3</sub> receptor antagonist, in patients with gastroparesis

Alimentary Pharmacology & Therapeutics2021-06-2024 citations